Edap TMS SA (EDAP)
2.47
-0.02
(-0.80%)
USD |
NASDAQ |
Nov 22, 16:00
2.47
0.00 (0.00%)
After-Hours: 20:00
Edap TMS Cash from Financing (Quarterly): 0.6422M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.6422M |
| June 30, 2024 | -1.362M |
| March 31, 2024 | -0.1814M |
| December 31, 2023 | 0.3802M |
| September 30, 2023 | -0.4548M |
| June 30, 2023 | -0.7172M |
| March 31, 2023 | -0.1944M |
| December 31, 2022 | 1.371M |
| Date | Value |
|---|---|
| September 30, 2022 | 21.52M |
| June 30, 2022 | 1.094M |
| March 31, 2022 | -1.058M |
| December 31, 2021 | -0.0556M |
| September 30, 2021 | -0.5132M |
| June 30, 2021 | 26.03M |
| March 31, 2021 | -1.482M |
| March 31, 2020 | 3.532M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.482M
Minimum
Mar 2021
26.03M
Maximum
Jun 2021
3.034M
Average
-0.1185M
Median
Cash from Financing (Quarterly) Benchmarks
| DBV Technologies SA | 0.007M |
| Cellectis SA | -4.218M |
| Genfit SA | -- |
| Adaptimmune Therapeutics PLC | 25.00M |
| Akari Therapeutics PLC | -0.443M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.573M |
| Cash from Investing (Quarterly) | -1.120M |
| Free Cash Flow | -24.95M |
| Free Cash Flow Per Share (Quarterly) | -0.1797 |
| Free Cash Flow to Equity (Quarterly) | -7.677M |
| Free Cash Flow to Firm (Quarterly) | -6.693M |
| Free Cash Flow Yield | -27.21% |